Neoadjuvant chemotherapy paclitaxel + doxorubicin (PD) vs fluorouracil + doxorubicin + cyclophosphamide (FAC) in locally advanced breast cancer: Clinical and pathological response

Семиглазов, Владимир; Bojok, A.A.; Arsumanov, A.S.; Иванова, О. А.; Иванов, В. Г.; Semiglazov, V.V.; Pozharissky, K. M.; Топузов, Э Э; Нургазиев, К Ш; Палтуев, Р. М.

doi:10.1016/s0959-8049(01)81098-4

Cited by 6 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Semiglazov et al (76) have compared paclitaxel plus anthracycline with FAC in a randomized Phase II trial in locally advanced breast cancer. In total, 103 patients received four cycles of either doxorubicin 60 mg/m 2 plus paclitaxel 200 mg/m 2 every 3 weeks or standard FAC (5-fluorouracil 600 mg/m 2 , doxorubicin 60 mg/m 2 , and cyclophosphamide 600 mg/ m 2 ) every 3 weeks.…”

Section: Paclitaxel Monotherapymentioning

confidence: 99%

Evidence-Based Use of Neoadjuvant Taxane in Operable and Inoperable Breast Cancer

Estévez

Gradishar

2004

Clinical Cancer Research

View full text Add to dashboard Cite

Neoadjuvant chemotherapy (NC) is standard therapy for patients with locally advanced breast cancer and is increasingly used for early-stage operable disease. The aim of NC is a pathological complete response (pCR) in the breast and axillary lymph nodes, which is the best predictor of improved outcome and prolonged survival. The taxanes docetaxel and paclitaxel are potent agents in breast cancer management, with promising single-agent activity and acceptable tolerability in the neoadjuvant setting. In this review of the taxanes as NC for operable and inoperable breast cancer, we include all fully published Phase II-III studies enrolling >30 patients. Current evidence suggests that the sequential administration of taxane-and anthracycline-based therapy may be superior to concomitant administration. Indeed, until the recent Phase III Aberdeen study (n ‫؍‬ 162), it was uncertain whether NC could prolong survival. In this study, sequential docetaxel after anthracycline-based NC significantly enhanced the clinical response rate and pathological complete response, and yielded a significant 3-year survival advantage, versus anthracyclinebased NC alone. Recently, the Phase III National Surgical Adjuvant Breast and Bowel Project (NSABP) trial B27 trial (n ‫؍‬ 2411) showed that sequential docetaxel after doxorubicin-cyclophosphamide significantly increased both clinical and pathological response rates for operable breast cancer, with the benefit evident in both estrogen receptorpositive and estrogen receptor-negative patients. This apparent superiority of a sequential anthracycline-taxane regimen is limited to docetaxel, with no similar Phase III trials of paclitaxel versus a non-taxane-based comparator having been conducted to date. In conclusion, current evidence supports the inclusion of a taxane in NC schedules for patients with large and locally advanced breast cancer.

show abstract

Section: Paclitaxel Monotherapymentioning

confidence: 99%

Evidence-Based Use of Neoadjuvant Taxane in Operable and Inoperable Breast Cancer

Estévez

Gradishar

2004

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

“…Le taux de pCR (5,6 %) obtenu dans notre sé rie est en accord avec les ré sultats de la litté rature internationale ; en effet le taux rapporté aprè s une chimiothé rapie né oadjuvante par anthracyclines avec un nombre de trois à quatre cycles est compris entre 3 % et 17 %, cette variabilité est due à l'hé té rogé né ité des effectifs inclus dans ces é tudes, les paramè tres cliniques et histologiques sont difficilement comparables [3][4][5][6][7][8][9][10][11][12][13].…”

Section: Re´ponse Histologique Comple`te (Pcr)unclassified

Chimiothérapie néoadjuvante par anthracyclines dans le cancer du sein : facteurs prédictifs de réponse

Bensouda

Ismaili

Ahbeddou

et al. 2011

Gynécologie Obstétrique & Fertilité

View full text Add to dashboard Cite

“…In locally advanced disease, Semiglazov et al [29] reported a pCR rate of 25% with four courses of AP (doxorubicin and paclitaxel) vs. 10% for patients treated with four cycles of FEC. In the AngloCeltic Cooperative Oncology Group study, 363 patients with stages II-III disease were randomly assigned to either AD (doxorubicin and docetaxel) or AC for six courses.…”

Section: Anthracycline-taxane Combinationsmentioning

confidence: 99%

Neoadjuvant chemotherapy for “Triple Negative” breast cancer: a review of current practice and future outlook

Nahleh

2009

Med Oncol

View full text Add to dashboard Cite

Patients with breast cancer who achieve a complete pathologic response (pCR) after preoperative (neoadjuvant) chemotherapy have an improved prognosis compared to those with residual disease; pCR being a good surrogate of long-term survival and cure from breast cancer. Despite their relative chemosensitivity, less than 25% of all patients with HER2/neu negative (0-2+), and hormone receptors (HR) negative tumors, so-called "Triple Negative" breast cancer (TNBC) treated with standard preoperative chemotherapy achieve pCR. Among patients with residual disease (no pCR) following neoadjuvant chemotherapy, patients with TNBC have the worst prognosis and overall survival. These patients lack the benefit of subsequent targeted therapy. Many studies have addressed improving the efficacy of neoadjuvant chemotherapy by including different cytotoxic agents, biologic modifiers, regimens, and schedules. Up to now, apart from trastuzumab for HRE2/neu+ tumors, none of the targeted agents can be considered a standard therapeutic option for primary systemic treatment. We hereby review the current literature on neoadjuvant chemotherapy for breast cancer, emphasizing treatment of TNBC. We also discuss potentially new therapeutic strategies that target this high risk group.

show abstract

Neoadjuvant chemotherapy paclitaxel + doxorubicin (PD) vs fluorouracil + doxorubicin + cyclophosphamide (FAC) in locally advanced breast cancer: Clinical and pathological response

Cited by 6 publications

References 0 publications

Evidence-Based Use of Neoadjuvant Taxane in Operable and Inoperable Breast Cancer

Evidence-Based Use of Neoadjuvant Taxane in Operable and Inoperable Breast Cancer

Chimiothérapie néoadjuvante par anthracyclines dans le cancer du sein : facteurs prédictifs de réponse

Neoadjuvant chemotherapy for “Triple Negative” breast cancer: a review of current practice and future outlook

Contact Info

Product

Resources

About